Home » News

Oral Estybon Shows Activity In Myelodysplastic Syndromes (ASH 2011)

One Comment By
Published: Feb 14, 2012 9:13 am
Oral Estybon Shows Activity In Myelodysplastic Syndromes (ASH 2011)

An oral formulation of Estybon shows activity and is safe in patients with myelo­dysplastic syndromes, according to results of a Phase 1 study.

The study investigators found that the optimal dose for oral Estybon was 560 mg twice daily for two weeks of a three-week treatment cycle. The most common observed side effects were problems involving urination, such as painful urination and blood in the urine.

The findings were presented during a poster session at the 2011 American Society of Hematology (ASH) meeting in December.

Estybon (rigosertib, ON 01910.Na)  is an investigational drug, not yet approved by the Food and Drug Administration for use outside of clinical trials. The biopharmaceutical company Onconova Therapeutics is developing Estybon as a potential new treatment for MDS. Estybon works by selectively killing cancer cells and immature stem cells (called blasts).

Recent Phase 1/2 trial results showed that Estybon is effective in MDS patients when administered intravenously (see related Beacon news).   The intravenous formulation is being tested further as an MDS treatment in an ongoing Phase 3 trial.

In the current Phase 1 study, researchers evaluated the safety and activity of oral Estybon at different doses in 33 MDS patients. All study participants were resistant to the MDS drugs Revlimid (lenalidomide), Vidaza (azacitidine), and Dacogen (decitabine).

The patients received 70 mg to 700 mg of oral Estybon twice daily for two weeks of a three-week treatment cycle.

After treatment with Estybon, 6 percent of patients achieved a complete response and 12 percent showed improvements in red blood cell counts.  The study investigators described these results as encouraging.

The researchers also said that treatment with Estybon was well tolerated. The most common side effects were urinary symptoms: painful urination, blood in urine, frequent urination, nighttime urination, and urinary bladder inflammation. The frequency of these symptoms was much higher in patients treated at the 700 mg level (83 percent), compared to those treated at the 560 mg level (29 percent).

Side effects related to urination also have been observed in trials of the intravenous formulation of Estybon.

One patient in the trial of oral Estybon experienced dose-limiting side effects at the 700 mg dose level during the first treatment cycle. Based on that finding, the researchers recommended a dose of 560 mg of Estybon for a Phase 2 trial.

For more information, please see abstract 3797 at the ASH 2011 meeting website.

Photo by Pink Sherbert Photography on Flickr – some rights reserved.
Tags: , , , , ,

Related Articles:

One Comment »

  • Alberto said:

    Hi …. do you know if it is possible to obtain Estybon (pill or injections) in Italy? Are there any medical centers in Italy that are participating in medical trails of this medicine? My mom lives in Italy, could she participate in any trials in US remotely? Thank you, Alberto